JP2011513399A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513399A5
JP2011513399A5 JP2010549646A JP2010549646A JP2011513399A5 JP 2011513399 A5 JP2011513399 A5 JP 2011513399A5 JP 2010549646 A JP2010549646 A JP 2010549646A JP 2010549646 A JP2010549646 A JP 2010549646A JP 2011513399 A5 JP2011513399 A5 JP 2011513399A5
Authority
JP
Japan
Prior art keywords
subject
composition
administered
composition according
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/001330 external-priority patent/WO2009114085A2/en
Publication of JP2011513399A publication Critical patent/JP2011513399A/ja
Publication of JP2011513399A5 publication Critical patent/JP2011513399A5/ja
Pending legal-status Critical Current

Links

JP2010549646A 2008-03-03 2009-03-03 同種癌細胞による免疫療法 Pending JP2011513399A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3342508P 2008-03-03 2008-03-03
PCT/US2009/001330 WO2009114085A2 (en) 2008-03-03 2009-03-03 Allogeneic cancer cell-based immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014138932A Division JP2014208690A (ja) 2008-03-03 2014-07-04 同種癌細胞による免疫療法

Publications (2)

Publication Number Publication Date
JP2011513399A JP2011513399A (ja) 2011-04-28
JP2011513399A5 true JP2011513399A5 (enExample) 2012-01-12

Family

ID=41065702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010549646A Pending JP2011513399A (ja) 2008-03-03 2009-03-03 同種癌細胞による免疫療法
JP2014138932A Pending JP2014208690A (ja) 2008-03-03 2014-07-04 同種癌細胞による免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014138932A Pending JP2014208690A (ja) 2008-03-03 2014-07-04 同種癌細胞による免疫療法

Country Status (11)

Country Link
US (2) US8475785B2 (enExample)
EP (2) EP2752193B1 (enExample)
JP (2) JP2011513399A (enExample)
KR (1) KR20110009095A (enExample)
CN (1) CN102014937A (enExample)
AU (1) AU2009223838B2 (enExample)
CA (1) CA2717854C (enExample)
DK (1) DK2257301T3 (enExample)
ES (1) ES2460899T3 (enExample)
IL (1) IL207958A (enExample)
WO (1) WO2009114085A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2285832T3 (es) * 1998-02-20 2007-11-16 Univ Miami Complejo de peptido antigenico-proteina de choque termico modificada.
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
EP2358383A4 (en) * 2008-11-21 2011-11-23 Univ Miami HIV / SIV VACCINES FOR THE MANUFACTURE OF SLEEPAGE AND SYSTEM IMMUNITY
KR20130113953A (ko) * 2010-05-21 2013-10-16 유니버시티 오브 마이애미 암 치료
EP2804626B1 (en) * 2012-01-20 2019-05-01 Fernando Thome Kreutz Autologous cancer cell vaccine
WO2015131176A1 (en) * 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2018199318A1 (ja) * 2017-04-28 2018-11-01 国立大学法人高知大学 抗ｇｐｃ－１抗体
DE102021124078A1 (de) 2021-09-17 2023-03-23 Timm Golüke Kosmetikzusammensetzung zur Anwendung auf der Haut

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5217891A (en) 1987-07-28 1993-06-08 Chiron Corporation DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides
WO1989012455A1 (en) 1988-06-15 1989-12-28 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
WO1990002564A1 (en) 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1991002077A1 (en) 1989-07-28 1991-02-21 The United States Of America, Represented By The Secretary, United States Department Of Commerce Efficient directional genetic cloning system
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
ATE154759T1 (de) 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
GB9200949D0 (en) 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
FR2688227A1 (fr) 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FI944102A7 (fi) 1992-03-09 1994-09-07 Istituto Naz Per Lo Studio E La Kasvaimen kasvua estämään kykenevä proteiiniyhdiste
EP0636248A4 (en) 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
CN1119459A (zh) 1993-03-19 1996-03-27 柏伦格-英格尔海姆国际股份公司 肿瘤疫苗的制备方法
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
WO1995004824A1 (en) 1993-08-05 1995-02-16 Medvet Science Pty. Ltd. Generation of dna libraries and retroviral vectors for same
US5705159A (en) 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5444087A (en) 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP0769932B1 (en) 1994-07-08 1998-10-14 Baxter International Inc. Implanted device containing tumor cells for the treatment of cancer
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
EP0784483B1 (en) 1994-10-03 2000-11-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
AU712907B2 (en) 1995-08-18 1999-11-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious diseases and compositions useful in same
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
EP0851765A4 (en) 1995-09-13 2000-01-19 Univ Fordham THERAPEUTIC AND PROPHYLACTIC PROCESSES THAT USE HEAT SHOCK PROTEINS
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
JP2000516911A (ja) 1996-03-28 2000-12-19 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ オプソニン強化細胞、および抗原に対する免疫応答を調節する方法
US5747332A (en) 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
AU736318B2 (en) 1996-11-26 2001-07-26 Nventa Biopharmaceuticals Corporation Immune responses using compositions containing stress proteins
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
ES2284199T5 (es) 1997-01-28 2011-11-14 Human Genome Sciences, Inc. Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l).
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US20040136951A1 (en) 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
ES2285832T3 (es) * 1998-02-20 2007-11-16 Univ Miami Complejo de peptido antigenico-proteina de choque termico modificada.
ATE428441T1 (de) 1998-05-26 2009-05-15 Genitrix Llc Zusammensetzungen und verfahren zur modulation einer immunantwort auf ein antigen durch verabreichung von zytokine-beladenen zellen
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
US6317435B1 (en) 1999-03-08 2001-11-13 Qualcomm Incorporated Method and apparatus for maximizing the use of available capacity in a communication system
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
WO2001078655A2 (en) 2000-04-17 2001-10-25 Alan Houghton Methods and compositions for heat shock protein mediated immunotherapy of melanoma
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
BR0111956A (pt) 2000-06-26 2003-05-13 Stressgen Biotechnologies Corp Tratamento do vìrus do papiloma humano
DK1363938T3 (en) 2000-08-03 2014-03-24 Univ Johns Hopkins Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US20070292411A1 (en) 2000-11-08 2007-12-20 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20060062786A1 (en) 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214210A1 (en) 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030044386A1 (en) 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003053338A2 (en) 2001-11-16 2003-07-03 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Novel chimeric rev, tat, and nef antigens
US7955845B2 (en) 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US20050214206A1 (en) 2001-12-20 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214207A1 (en) 2001-12-20 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind toTRAIL receptors
US20050214208A1 (en) 2001-12-20 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214205A1 (en) 2001-12-20 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
EP1539197A4 (en) * 2002-02-01 2006-08-02 Univ Jefferson TREATMENT OF TUMOR CELLS FOR USE IN IMMUNOTHERAPY IN CANCER
EP1578773A3 (en) 2002-02-28 2005-12-14 Antigenics Inc. Methods and products based on oligomerization of stress proteins
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
JP2006501147A (ja) 2002-04-25 2006-01-12 ユニバーシティー オブ コネティカット ヘルス センター 非ワクチン治療法の治療効果を改善するための熱ショックタンパク質の使用
AU2003234469A1 (en) 2002-05-02 2003-11-17 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
US20070298041A1 (en) 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
EP1534336A4 (en) 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS
US7629440B2 (en) 2002-08-20 2009-12-08 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP4892705B2 (ja) 2002-08-20 2012-03-07 オプサニテクス エルエルシー レクチン組成物および抗原に対する免疫反応を調節するための方法
CA2501744C (en) 2002-10-09 2012-01-03 Central Iowa Health System Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
JP2006512942A (ja) 2002-10-25 2006-04-20 ユニバーシティー オブ コネティカット ヘルス センター 制御細胞溶解による癌の免疫療法のための装置と方法
US8877204B2 (en) 2003-02-20 2014-11-04 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
AU2003223226A1 (en) 2003-02-20 2004-09-17 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
CA2517274C (en) 2003-02-27 2012-09-18 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
RU2399381C2 (ru) 2003-02-28 2010-09-20 Антидженикс Инк. Использование лектинов для активации олигомеризации гликопротеидов и антигенных молекул
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP1633316A4 (en) 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
KR100499278B1 (ko) * 2003-07-05 2005-07-01 학교법인 포항공과대학교 로텍산 화합물이 공유결합된 고체 기판 및 이를 이용한바이오칩
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
CA2540283C (en) 2003-09-26 2019-05-21 University Of Miami Tumor vaccine
ATE448312T1 (de) 2003-09-26 2009-11-15 Merck Serono Sa Leitsequenzen zur verwendung bei der produktion von proteinen
FR2867982B1 (fr) * 2004-03-26 2007-07-20 Jean Marie Andrieu Procede pour amplifier l'activite de vaccins therapeutiques
WO2005113003A2 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
WO2005120558A2 (en) 2004-05-25 2005-12-22 University Of Connecticut Health Center Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
PL3428191T3 (pl) 2004-10-06 2025-04-07 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
JP5122983B2 (ja) 2005-02-24 2013-01-16 メディカル リサーチ カウンシル Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
WO2007030531A2 (en) 2005-09-06 2007-03-15 Molecular Image Inc. Reagents for testing and molecular imaging of liver cancer
CN101057975B (zh) 2006-12-13 2012-10-10 中国科学院微生物研究所 一种抗免疫耐受性和免疫缺陷性病毒的鸡尾酒疫苗及其应用
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
AU2007339773B2 (en) 2006-12-27 2011-03-10 The Johns Hopkins University Compositions and methods for stimulating an immune response
CN102317303A (zh) 2007-07-31 2012-01-11 约翰·霍普金斯大学 用于肿瘤或感染性疾病的免疫预防或免疫治疗的多肽-核酸偶联物
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
IL190438A0 (en) 2008-03-25 2008-12-29 K M B Y Ltd A method of setting a drill for drilling a hole in a bone coaxial to the hole in the nail and aiming device for realizing this method
PT2260145E (pt) 2008-03-26 2012-09-18 Clariant Finance Bvi Ltd Composições de branqueamento ótico melhoradas
KR101612275B1 (ko) 2008-04-02 2016-04-14 사노피 악티노마두라 나미비엔시스로부터 유래된 고도로 브릿징된 펩타이드
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2358383A4 (en) 2008-11-21 2011-11-23 Univ Miami HIV / SIV VACCINES FOR THE MANUFACTURE OF SLEEPAGE AND SYSTEM IMMUNITY
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP2387415A1 (en) 2009-01-16 2011-11-23 AGIRx Limited Vaccine compositions
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
WO2010115118A2 (en) 2009-04-03 2010-10-07 Antigenics, Inc. Methods for preparing and using multichaperone-antigen complexes
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
WO2011069528A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Lyophilization of nucleic acids in lactate-containing solutions
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
JP6066732B2 (ja) 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
US8865653B2 (en) 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
KR20130113953A (ko) 2010-05-21 2013-10-16 유니버시티 오브 마이애미 암 치료
EP2678031A4 (en) 2011-02-23 2015-09-02 Univ Miami COMBINED VACCINATION WITH CELL-BASED GP96-IG-SIV / HIV AND THE RECOMBINANT PROTEIN GP120 FOR PROTECTION AGAINST SIV / HIV
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
JP6518199B6 (ja) 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
WO2014140884A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands

Similar Documents

Publication Publication Date Title
JP2011513399A5 (enExample)
JP2011515399A5 (enExample)
AR076670A1 (es) Anticuerpos humanizados especificos de la forma protofibrilar del peptido beta-amiloide.
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
JP2011079858A5 (enExample)
EA201400173A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CL2014000225A1 (es) Compuestos derivados de 1,2,4-triazol; composicion farmaceutica; procedimiento de preparacion de procursores de los mismos y el uso como moduladores del transporte nuclear en el tratamiento de enfermedades tales como cancer.
EP4353818A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
EA201400172A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2008002111A1 (es) Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
JP2017524031A5 (enExample)
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
JP2009525051A5 (enExample)
JP2015517488A5 (enExample)
CO7131367A2 (es) Formulación compuesta que comprende una tableta esferoidal de múltiples unidades (must) en cápsulada en cápsula dura y método para su preparación
JP2014502628A5 (enExample)
NZ701205A (en) Optimised subcutaneous therapeutic agents
JP2015507020A5 (enExample)